<DOC>
	<DOC>NCT02874846</DOC>
	<brief_summary>To evaluate effect of Netarsudil Ophthalmic Solution 0.02% on Nocturnal and Diurnal Intraocular Pressure.</brief_summary>
	<brief_title>Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1. 18 years of age or older. 2. Ocular hypertension or openangle glaucoma in both eyes. 3. Unmedicated intraocular pressure &gt; 17 mmHg in one or both eyes and &lt; 30 mmHg in both eyes. 4. Corrected visual acuity in each eye equivalent to 20/200 or better. 5. Able and willing to give signed informed consent and follow study instructions. 1. Glaucoma with pseudoexfoliation or pigment dispersion component, history of angle closure, narrow angles. 2. Intraocular pressure ≥ 30 mmHg. 3. Use of ocular medications within 30 days. 4. Known hypersensitivity to any component of the test formulations or to medications used routinely during a clinical eye examination. 5. Previous eye surgery (other than cataract). 6. Ocular trauma within 6 months. 7. Clinically significant ocular disease that might interfere with the study. 8. Central corneal thickness greater than 620 µm.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>